Moderna, Inc. (ETR:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
36.00
+1.49 (4.33%)
At close: Jan 16, 2026
6.65%
Market Cap14.09B
Revenue (ttm)1.90B
Net Income (ttm)-2.66B
Shares Outn/a
EPS (ttm)-6.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,535
Average Volume20,354
Open34.14
Previous Close34.51
Day's Range34.00 - 36.23
52-Week Range19.37 - 43.26
Beta1.17
RSI76.25
Earnings DateFeb 20, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Arbutus Biopharma Shares Fall 19% On European Patent Revocation

(RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents, EP2279254, after years of opposition pro...

2 days ago - Nasdaq

Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges

Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges

2 days ago - GuruFocus

Arbutus falls as patent dispute with Moderna hits EU snag

Arbutus (ABUS) stock sinks as the European Patent Office revokes a patent that was subject to a legal dispute between the company and Moderna (MRNA). Read more here.

2 days ago - Seeking Alpha

This COVID-Era Biotech Favorite Is Surging Once Again On Strong Q4 Guidance: Momentum Score Spikes

Massachusetts-based Moderna Inc. (NASDAQ: MRNA) is seeing fresh momentum in recent weeks, with the stock off to a flying start in 2026. The company that rose to prominence during the COVID-19 pandemi...

3 days ago - Benzinga

Notable ETF Outflow Detected - LABU, RVMD, MRNA, KRYS

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have...

3 days ago - Nasdaq

Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know

Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.

4 days ago - Nasdaq

Noteworthy Wednesday Option Activity: ISRG, XOM, MRNA

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Intuitive Surgical Inc (Symbol: ISRG), where a total of 13,598 contracts have traded so far, rep...

4 days ago - Nasdaq

Moderna Stock Gets Healthy Relative Strength Rating Jump

A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?

5 days ago - Investor's Business Daily

Moderna (MRNA) Shares Surge by Nearly 13%

Moderna (MRNA) Shares Surge by Nearly 13%

5 days ago - GuruFocus

Stocks making the biggest moves midday: JPMorgan, Moderna, Boeing, Cardinal Health, Chipotle & more

These are some of the stocks posting the largest midday moves.

5 days ago - CNBC

Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Tuesday. Shares of Moderna Inc (NASDAQ: MRNA) rose sharply during Tuesday's session the company provided updates on its b...

5 days ago - Benzinga

Moderna Inc at JPMorgan Healthcare Conference Transcript

Moderna Inc at JPMorgan Healthcare Conference Transcript

6 days ago - GuruFocus

Monday Sector Laggards: Healthcare, Energy

In afternoon trading on Monday, Healthcare stocks are the worst performing sector, showing a 0.7% loss. Within that group, Moderna Inc (Symbol: MRNA) and Baxter International Inc (Symbol: BAX) are two...

6 days ago - Nasdaq

Moderna Raises 2025 Forecast, Targets Major Vaccine And Cancer Readouts In 2026

(RTTNews) - Moderna (MRNA) heads into 2026 with stronger finances and a crowded late-stage pipeline after an aggressive cost reset in 2025 and a slate of regulatory and clinical milestones lined up fo...

6 days ago - Nasdaq

Moderna Stock Jumps, Then Turns Negative: What's Happening?

Moderna shares are volatile Monday after ... Full story available on Benzinga.com

6 days ago - Benzinga

Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026

Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026

6 days ago - GuruFocus

Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance.

Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.

6 days ago - Barrons

Moderna expects $1.9 billion in sales, trims costs forecast for 2025

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its previously projected $1.6  billion to $2  billion forecast but well below reven...

6 days ago - Reuters

Moderna, Inc.: Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q...

6 days ago - Finanz Nachrichten

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 ...

6 days ago - Wallstreet:Online